Cellectis S.A. (FRA:ZVA)

Market Cap	219.69M +114.6%
Revenue (ttm)	65.14M +37.2%
Net Income	-58.31M
EPS	-0.58
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	2.892
Previous Close	2.970
Day's Range	2.892 - 2.892
52-Week Range	1.200 - 4.655
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 11, 2026

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 229
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: ZVA

Financial Performance

In 2025, Cellectis's revenue was $79.59 million, an increase of 61.72% compared to the previous year's $49.22 million. Losses were -$67.59 million, 83.9% more than in 2024.

Financial numbers in USD